Research Topics
| Carmelo RizzariSummaryAffiliation: Ospedale San Gerardo Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Outcome of very late relapse in children with acute lymphoblastic leukemiaCarmelo Rizzari
Pediatric Department of Monza, Italy
Haematologica 89:427-34. 2004..The present study was aimed at investigating clinical features and treatment outcome of children with very late relapse, diagnosed and treated in Italy in the last 20 years...- A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemiaCarmelo Rizzari
Department of Pediatric Hematology Oncology, University of Milano Bicocca, S Gerardo Hospital, Monza, Italy
Haematologica 91:24-31. 2006..The main goal of the present study was to investigate the pharmacological effects of the administration of PEG-ASP given as a first-line product in children with ALL... - Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studiesAndrea Biondi
Centro Ricerche Leucemie Infantili M Tettamanti, Clinica Pediatrica Università Milano Bicocca, Monza, Italy
Haematologica 91:534-7. 2006..The corresponding figures for patients treated in the ALL-91 high-risk protocol (reduced induction and nine blocks) were one of seven patients treated with chemotherapy only and none of two who were transplanted... 
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual diseaseCarmelo Rizzari
Department of Pediatrics, S Gerardo Hospital, Via Pergolesi 33, Monza, Italy
Expert Rev Anticancer Ther 11:1391-401. 2011..This article is focused on the current available information on MRD as a prognostic marker in childhood AML...- Optimizing asparaginase therapy for acute lymphoblastic leukemiaCarmelo Rizzari
Department of Pediatrics, San Gerardo Hospital, University of Milano Bicocca, Monza, Italy
Curr Opin Oncol 25:S1-9. 2013..Based on the indications of different protocols, lack of cross-reactivity to the E. coli-derived products and taking into consideration regulatory factors and availability, crisantaspase may be considered a viable second-line therapy... - FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemiaPaolo Arrigoni
Centro Ricerca M. Tettamanti, , Monza, Italy
Br J Haematol 120:89-92. 2003..5%, P = 0.29). In APL patients, FLT3/ITD was strongly correlated to a higher white blood cell count at diagnosis and the M3 French-American-British subtype... - Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapyMaurizio Arico
Pediatric Hematology Oncology, Ospedale dei Bambini G Di Cristina, Palermo, Italy
J Clin Oncol 26:283-9. 2008..The prognostic value of DNA index was explored in this setting... - Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemiaAndrea Pession
Associazione Italiana di Ematologia Oncologia Pediatrica AIEOP, University of Bologna, Bologna, Italy
J Clin Oncol 23:7161-7. 2005.... - Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 studyMaurizio Arico
Oncoematologia Pediatrica, Ospedale dei Bambini G Di Cristina, 90134 Palermo, Italy
Haematologica 90:1186-91. 2005..The aim of this study was to evaluate the efficacy of treatment reduction in a subset of children with ALL at minimal risk of failure... 
Ancestry and pharmacogenetics of antileukemic drug toxicityShinji Kishi
Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
Blood 109:4151-7. 2007..026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy...- Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol IIMaurizio Arico
Onco Ematologia Pediatrica, Ospedale dei Bambini G Di Cristina, Palermo, Italy
Blood 100:420-6. 2002..This modified therapy may lead to high cure rates for patients defined as at high risk for intrinsic resistance to corticosteroids only...